Drug intelligence / Profile preview

insulin detemir + insulin glargine

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

A combination of two long-acting insulin analogs used for the treatment of diabetes mellitus. Both insulin detemir and insulin glargine are modified forms of insulin that provide basal insulin coverage with different pharmacokinetic profiles. Insulin detemir typically requires twice-daily dosing while insulin glargine is usually administered once daily. When used in combination, they can provide extended basal insulin coverage but may increase the risk of hypoglycemia due to their overlapping mechanisms of action.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin detemir + insulin glargine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin detemir + insulin glargine.

Explore the full profile